Get the Daily Brief
Latest Biotech News
Regulators expand immunotherapy options in solid tumors
The FDA approved atezolizumab plus chemotherapy for adjuvant treatment of stage III dMMR colon cancer after the phase III ATOMIC trial, cutting the risk of recurrence or death by about 50%. The...
Biotech IPOs underscore renewed appetite for immune-focused pipelines
TRex Bio priced a $117 million IPO (TRXB) to fund early clinical development of regulatory T cell–targeting immunotherapies in autoimmune and inflammatory disease. The company is building around...
Clinical trial data reshape preoperative head-and-neck strategies
A phase II trial reported that preoperative chemo-immunotherapy with sintilimab achieved major pathological responses in 59.1% of patients with locally advanced head and neck cancer. Responders...
Oncology biology identifies new immune escape levers
New research shows that the macrophage enzyme MMP14 generates soluble semaphorin 4D, which helps build an immunosuppressive tumor microenvironment and excludes anti-cancer T cells. The study links...
New translational approaches for delivering targeted gene therapy
A review reaffirms that beremagene geperpavec, the first FDA-approved topical gene therapy, improves wound healing in dystrophic epidermolysis bullosa. The source notes durability depends on...
Cancer diagnostics: blood-based ratios point to earlier risk stratification
A single-center study of 127 patients suggests that a preoperative fibrinogen-to-albumin ratio independently predicts muscle-invasive and locally advanced upper tract urothelial carcinoma....
On-device or AI-enabled diagnostics inch toward deployment but validation gaps remain
A two-center study trained a deep learning radiomics model on routine breast ultrasound images to predict sentinel lymph node metastasis preoperatively. The model achieved moderate discrimination...
New mechanistic cancer-targeting strategies emerge from molecular reviews
A new iMetaMed review positions cysteine peptidases—such as cathepsins B, S, L, and X—as master switches that regulate antigen presentation and tumor immune evasion. By mapping how lysosomal...
Neurology therapeutics: engineered protein therapy targets Fragile X circuitry
A UC Riverside team, funded by FRAXA, plans to test engineered proteins designed to cross the blood–brain barrier and normalize brain activity in Fragile X syndrome mice. The approach aims to...
Drug safety and discovery tooling: novel screening and analytics expand capabilities
Researchers reported a cost-effective HPLC workflow that separates both epimers of the antibiotic prodrug cefpodoxime proxetil in human plasma while characterizing its active metabolite and...
Regulatory approvals and pricing moves in oncology and radiopharmaceuticals
The FDA approved atezolizumab plus chemotherapy for stage III dMMR colon cancer after the phase III ATOMIC trial showed a 50% reduction in the risk of recurrence or death (ID: 90b86c0bfc9d02ec)....
Biotech IPOs and capital formation for immune and hypertension programs
TRex Bio priced an IPO that raised $117 million to advance Treg-activating immune therapies, following a prior $116.7 million pricing report (IDs: 6251274018ba548d, 46d8bcd99961ee3c). The...
Targeted therapeutics and biomarkers—predicting immunotherapy benefit in lung cancer
A new study reports that a simple blood test score—combining hemoglobin with the albumin-to-alkaline phosphatase ratio—can predict which advanced lung cancer patients benefit from immunotherapy...
Clinical trial efficacy in oncology—ADC and PARP combinations
A phase Ib/II trial in China reported that the oral PARP inhibitor HTMC0435 combined with temozolomide produced a manageable safety profile, a 25% response rate, and 11.2-month median overall...
Imaging and pathology AI—mismatch between accuracy and real-world readiness
A review in Journal of Translational Medicine concludes that autonomous agentic AI is technically feasible in computational pathology, but clinical evidence is insufficient for real-world...
Cell and gene pipeline: in vivo CAR-T durability update
EsoBiotec reported extended follow-up on its in vivo BCMA CAR-T program ESO-T01 in relapsed/refractory multiple myeloma, with data updated through a maximum 15 months (ID: 4022394a218a8809). All...
Vaccine and infectious disease—antibody escape and Long COVID mechanistic failure
Deep sequencing from AMP trial breakthrough infections found that prophylactic VRC01 can drive low-frequency HIV escape mutations in roughly a third of treated participants, even as potent...
Regulatory and compliance oversight for pharma disclosures
A memorandum of understanding between the SEC and FDA formalizes information-sharing that increases dual oversight of corporate communications, according to BioXconomy (ID: 1c636c59b0329e52). The...
Venture funding: Matchpoint and immune-oncology oral chemistry
Matchpoint Therapeutics closed a $150 million Series B to advance oral covalent small molecules for autoimmune and inflammatory diseases (ID: 68b514e3e4f784f1). The financing supports progression...
Evidence gaps and diagnostics: limited benefit of delayed PET for lung nodules
A validated study of 612 patients found that adding delayed-phase 18F-FDG PET/CT to prediction models for indeterminate pulmonary nodules delivered only marginal gains, with calibration issues and...